NRIX
HealthcareNurix Therapeutics, Inc.
$17.49
$-0.57 (-3.16%)
Jan 5, 2026
Price History (1Y)
Analysis
Nurix Therapeutics, Inc. is a biotechnology company operating in the healthcare sector with a market capitalization of $1.77 billion and revenue of $83.69 million (TTM). The company has 286 employees. Financially, Nurix Therapeutics, Inc. reported negative profitability metrics, including a gross margin of -259.8%, an operating margin of -1157.7%, and a profit margin of -292.5%. Returns on equity and assets were also negative at -65.4% and -32.2%, respectively. The company's balance sheet shows $56.49 million in debt and $428.83 million in cash, resulting in a debt-to-equity ratio of 15.17. Nurix Therapeutics, Inc.'s valuation metrics include a forward P/E of -5.13 and an EV/EBITDA of -3.92. Revenue growth was -37.3% year-over-year (YoY), while earnings growth is not reported (N/A). The company does not pay dividends.
This analysis is AI-generated for informational purposes only and should not be considered financial advice. Data may be delayed or inaccurate. Always do your own research and consult a qualified financial advisor before making investment decisions.
About Nurix Therapeutics, Inc.
Nurix Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and antibody therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-5948, an orally bioavailable BTK degrader, that is in Phase 1B/2 clinical trials for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader, that is in Phase 1A clinical trials for the treatment of relapsed or refractory B-cell malignancies; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor, that is in Phase 1A clinical trials to treat immuno-oncology indications. It is also developing NX 0479/GS 6791, a IRAK4 degrader for the treatment of rheumatoid arthritis and other inflammatory diseases. The company has a strategic collaboration agreement with Gilead Sciences, Inc. (Gilead), Sanofi S.A. (Sanofi), and Pfizer Inc. (Pfizer) for co-development and co-commercialization for multiple drug candidates. The company was formerly known as Nurix Inc. and changed its name to Nurix Therapeutics, Inc. in October 2018. Nurix Therapeutics, Inc. was incorporated in 2009 and is headquartered in San Francisco, California.
Visit website →Key Statistics
- Market Cap
- $1.77B
- P/E Ratio
- N/A
- 52-Week High
- $22.50
- 52-Week Low
- $8.18
- Avg Volume
- 1.77M
- Beta
- 1.94
Company Info
- Industry
- Biotechnology
- Exchange
- NGM
- Country
- United States
- Employees
- 286